Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.

Eur J Cancer. 2018 Apr 13;96:6-16. doi: 10.1016/j.ejca.2018.03.012. [Epub ahead of print]

PMID:
29660598
2.

Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front.

Kunita A, Baeriswyl V, Meda C, Cabuy E, Takeshita K, Giraudo E, Wicki A, Fukayama M, Christofori G.

Am J Pathol. 2018 May;188(5):1276-1288. doi: 10.1016/j.ajpath.2018.01.016. Epub 2018 Feb 17.

PMID:
29458011
3.

Comparative Genomics of Completely Sequenced Lactobacillus helveticus Genomes Provides Insights into Strain-Specific Genes and Resolves Metagenomics Data Down to the Strain Level.

Schmid M, Muri J, Melidis D, Varadarajan AR, Somerville V, Wicki A, Moser A, Bourqui M, Wenzel C, Eugster-Meier E, Frey JE, Irmler S, Ahrens CH.

Front Microbiol. 2018 Jan 30;9:63. doi: 10.3389/fmicb.2018.00063. eCollection 2018.

4.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

PMID:
29066507
5.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A.

Oncotarget. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213. eCollection 2017 Sep 19.

6.

Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?

Prêtre V, Wicki A.

Semin Cancer Biol. 2018 Feb;48:70-77. doi: 10.1016/j.semcancer.2017.04.011. Epub 2017 May 1. Review.

PMID:
28473255
7.

Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.

Paasinen-Sohns A, Koelzer VH, Frank A, Schafroth J, Gisler A, Sachs M, Graber A, Rothschild SI, Wicki A, Cathomas G, Mertz KD.

Neoplasia. 2017 Mar;19(3):196-206. doi: 10.1016/j.neo.2017.01.003. Epub 2017 Feb 3.

8.

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations.

Nordmann TM, Juengling FD, Recher M, Berger CT, Kalbermatten D, Wicki A, Paasinen-Sohns A, Cathomas G, Tzankov A, Daikeler T.

Blood. 2017 Feb 16;129(7):879-882. doi: 10.1182/blood-2016-09-740217. Epub 2016 Dec 9.

9.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2016 Oct 10;16(1):780.

10.

AKT-ions with a TWIST between EMT and MET.

Tang H, Massi D, Hemmings BA, Mandalà M, Hu Z, Wicki A, Xue G.

Oncotarget. 2016 Sep 20;7(38):62767-62777. doi: 10.18632/oncotarget.11232. Review.

11.

Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.

Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD.

J Immunother Cancer. 2016 Aug 16;4:47. doi: 10.1186/s40425-016-0151-z. eCollection 2016.

12.

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Wicki A, Mandalà M, Massi D, Taverna D, Tang H, Hemmings BA, Xue G.

Physiol Rev. 2016 Jul;96(3):805-29. doi: 10.1152/physrev.00024.2015. Review.

13.

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.

Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD.

J Immunother Cancer. 2016 Mar 15;4:13. doi: 10.1186/s40425-016-0117-1. eCollection 2016.

14.

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.

Orleth A, Mamot C, Rochlitz C, Ritschard R, Alitalo K, Christofori G, Wicki A.

J Drug Target. 2016;24(1):80-9. doi: 10.3109/1061186X.2015.1056189. Epub 2015 Jul 23.

PMID:
26204325
15.

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.

Xue G, Zippelius A, Wicki A, Mandalà M, Tang F, Massi D, Hemmings BA.

J Natl Cancer Inst. 2015 Jun 11;107(7). pii: djv171. doi: 10.1093/jnci/djv171. Print 2015 Jul. Review.

PMID:
26071042
16.

Impaired tilt perception in Parkinson's disease: a central vestibular integration failure.

Bertolini G, Wicki A, Baumann CR, Straumann D, Palla A.

PLoS One. 2015 Apr 15;10(4):e0124253. doi: 10.1371/journal.pone.0124253. eCollection 2015.

17.

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.

Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Mamot C.

Int J Pharm. 2015 Apr 30;484(1-2):8-15. doi: 10.1016/j.ijpharm.2015.02.034. Epub 2015 Feb 18.

PMID:
25701632
18.

Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.

Wicki A, Witzigmann D, Balasubramanian V, Huwyler J.

J Control Release. 2015 Feb 28;200:138-57. doi: 10.1016/j.jconrel.2014.12.030. Epub 2014 Dec 26. Review.

PMID:
25545217
19.

The diagnostic value of magnetic resonance imaging measurements for assessing cervical spinal canal stenosis.

Rüegg TB, Wicki AG, Aebli N, Wisianowsky C, Krebs J.

J Neurosurg Spine. 2015 Mar;22(3):230-6. doi: 10.3171/2014.10.SPINE14346. Epub 2014 Dec 19.

PMID:
25525959
20.

Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.

Conen K, Mosna-Firlejczyk K, Rochlitz C, Wicki A, Itin P, Arnold AW, Gross M, Zimmermann F, Zippelius A.

Dermatology. 2015;230(1):1-4. doi: 10.1159/000365918. Epub 2014 Nov 29. Review.

PMID:
25472806
21.

[Stivarga shows effectiveness in practice].

Wicki A.

Rev Med Suisse. 2014 May 21;10(431):1109. French. No abstract available.

PMID:
24941679
22.

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.

Wicki A, Hermann F, Prêtre V, Winterhalder R, Kueng M, von Moos R, Rochlitz C, Herrmann R.

Oncol Res Treat. 2014;37(5):230-6. doi: 10.1159/000362376. Epub 2014 Apr 8.

PMID:
24853781
23.

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.

Wicki A, Wild D, Prêtre V, Mansi R, Orleth A, Reubi JC, Rochlitz C, Mamot C, Mäcke HR, Christofori G.

EJNMMI Res. 2014 Feb 16;4(1):9. doi: 10.1186/2191-219X-4-9.

24.

[Melanoma- finally good news].

Wicki A, Arnold AW, Itin PH, Zippelius A.

Praxis (Bern 1994). 2013 May 22;102(11):667-70. doi: 10.1024/1661-8157/a001293. Review. German.

PMID:
23692905
25.

Predicting the risk and severity of acute spinal cord injury after a minor trauma to the cervical spine.

Aebli N, Rüegg TB, Wicki AG, Petrou N, Krebs J.

Spine J. 2013 Jun;13(6):597-604. doi: 10.1016/j.spinee.2013.02.006. Epub 2013 Mar 21.

PMID:
23523437
26.

The Torg-Pavlov ratio for the prediction of acute spinal cord injury after a minor trauma to the cervical spine.

Aebli N, Wicki AG, Rüegg TB, Petrou N, Eisenlohr H, Krebs J.

Spine J. 2013 Jun;13(6):605-12. doi: 10.1016/j.spinee.2012.10.039. Epub 2013 Jan 11.

PMID:
23318107
27.

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C.

Lancet Oncol. 2012 Dec;13(12):1234-41. doi: 10.1016/S1470-2045(12)70476-X. Epub 2012 Nov 13.

PMID:
23153506
28.

Targeted therapies in breast cancer.

Wicki A, Rochlitz C.

Swiss Med Wkly. 2012 Apr 27;142:w13550. doi: 10.4414/smw.2012.13550. Review.

29.

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C.

J Drug Target. 2012 Jun;20(5):422-32. doi: 10.3109/1061186X.2012.680960. Epub 2012 Apr 23.

PMID:
22519893
30.

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C.

Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7.

31.

Diet and cancer.

Wicki A, Hagmann J.

Swiss Med Wkly. 2011 Sep 9;141:w13250. doi: 10.4414/smw.2011.13250. Review.

32.

Kras in metastatic colorectal cancer.

Wicki A, Herrmann R, Christofori G.

Swiss Med Wkly. 2010 Nov 19;140:w13112. doi: 10.4414/smw.2010.13112. Review.

33.

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR.

J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914.

34.

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.

Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, Kren A, Went P, Derksen PW, Berns A, Jonkers J, Christofori G.

EMBO J. 2008 Oct 8;27(19):2603-15. doi: 10.1038/emboj.2008.178. Epub 2008 Sep 4.

35.

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G.

Clin Cancer Res. 2007 Jun 15;13(12):3696-705.

36.

The potential role of podoplanin in tumour invasion.

Wicki A, Christofori G.

Br J Cancer. 2007 Jan 15;96(1):1-5. Epub 2006 Dec 19. Review.

37.

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Mäcke HR.

J Nucl Med. 2006 Dec;47(12):2025-33.

38.

Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton.

Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G.

Cancer Cell. 2006 Apr;9(4):261-72.

39.

Determination of the donor:host blood cell ratio after haematological stem cell transplant by means of semiquantitative detection of short tandem repeat polymorphisms.

Wicki A, Malik N, Gratwohl A, Tichelli A, Meyer-Monard S, Müller H.

Swiss Med Wkly. 2002 Jun 1;132(21-22):288-95.

PMID:
12362287
41.
42.

[Significance of hepatitis C virus antibodies in asymptomatic blood donors].

Zaugg PY, Joller-Jemelka HI, Skruzny Z, Frey-Wettstein M, Bernardi M, Havelka J, Wicki AN, Bühler H.

Schweiz Med Wochenschr. 1995 Apr 15;125(15):758-61. German.

PMID:
7537893
43.

The effect of plaque control in subjects with shallow pockets and high prevalence of periodontal pathogens.

al-Yahfoufi Z, Mombelli A, Wicki A, Lang NP.

J Clin Periodontol. 1995 Jan;22(1):78-84.

PMID:
7706543
44.

Hepatitis C RNA prevalence in a Western European organ donor pool and virus transmission by organ transplantation.

Candinas D, Joller-Jemelka HI, Schlumpf R, Wicki A, Mutimer DJ, Keusch G, Largiadèr F.

J Med Microbiol. 1994 Oct;41(4):220-3.

PMID:
7523676
45.

Detection of HBs antigen in "anti-HBc alone" positive sera.

Joller-Jemelka HI, Wicki AN, Grob PJ.

J Hepatol. 1994 Aug;21(2):269-72.

PMID:
7989721
46.

[Hepatitis serological finding "anti-HBc alone", circulating viral DNA and interpretation of findings].

Gross A, Joller-Jemelka HI, Wicki AN, Grob PJ.

Schweiz Med Wochenschr. 1993 Jun 12;123(23):1193-202. Review. German.

PMID:
8327866
47.

Indeterminate hepatitis C.

Wicki AN, Joller-Jemelka H.

Lancet. 1993 Jun 12;341(8859):1534. No abstract available.

PMID:
7685053
48.

[Polymerase chain reaction in hepatitis C: increased sensitivity via amplification of shorter cDNA fragments].

Schwery S, Wicki AN, Joller-Jemelka HI, Havelka J, Zala G, Schmid M, Bühler H.

Schweiz Med Wochenschr. 1993 May 15;123(19):965-9. German.

PMID:
8511526
49.

Improved detection of antibodies to hepatitis C virus by use of a new recombinant immunoblot assay.

Joller-Jemelka HI, Wicki AN, Opitz R.

Eur J Clin Microbiol Infect Dis. 1993 May;12(5):398-400. No abstract available.

PMID:
7689054
50.

Detection of hepatitis C viraemia in Caucasian patients with hepatocellular carcinoma.

Garson JA, Wicki AN, Ring CJ, Joller H, Zala G, Schmid M, Buehler H.

J Med Virol. 1992 Oct;38(2):152-6.

PMID:
1334130

Supplemental Content

Support Center